RxDoctor Payments Data

Daniel Benson, MD

Urology · Dallas, TXNPI 1629369772

Payments from drug & device makers

$627in general payments, 2019–2025

Across 29 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$140
  • Johnson & Johnson$137
  • Astellas Pharma US Inc$111
  • Travere Therapeutics, Inc.$46
  • BK Medical Holding Company Inc.$37
  • Healthtronics Stone Solutions, LLC$33
  • plus $123 from 7 others

What the payments were for

  • Food & beverage$627100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific3$140
Johnson & Johnson(3 entities)4$137
Astellas Pharma US Inc10$111
Travere Therapeutics, Inc.2$46
BK Medical Holding Company Inc.1$37
Healthtronics Stone Solutions, LLC1$33
Ferring Pharmaceuticals Inc.2$25
Amgen1$22
Bayer1$19
Dendreon Pharmaceuticals LLC1$16
Neotract Inc.1$15
Pfizer1$14
Cook Medical LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$627 in reported general payments places this provider in the 15th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$20,706
Medicare patients
233
Services billed
290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron142$85,095
Tamsulosin Hcl525$8,097
Finasteride186$2,922
Silodosin38$2,762
Alfuzosin Hcl ErAlfuzosin Hcl91$1,845
Estradiol14$882
Oxybutynin Chloride ErOxybutynin Chloride27$639
Ciprofloxacin Hcl11$76
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12$68

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$111$85,095142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 878 urology providers in Texas.

Other urology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →